Released : Jan 06, 2017 11:00



Director Declaration

January 6, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the 'Company') announces
that Ian Clark, Non-Executive Director of the Company, was appointed to the
Board of Directors of Kite Pharma, Inc. on January 5, 2017.

This notification is to satisfy the Company's obligations under LR 9.6.14R of
the UK Listing Rules.

Oliver Strawbridge
Senior Assistant Company Secretary

For further information please contact:

Investor Relations

Ian Karp                        ikarp@shire.com            +1 781 482 9018

Robert Coates                   rcoates@shire.com          +44 1256 894874

Media

Lisa Adler                      lisa.adler@shire.com       +1 617 588 8607

Debbi Ford                      debbi.ford@shire.com       +1 617 949 9083

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on serving people
with rare diseases and other highly specialized conditions. We strive to
develop best-in-class products, many of which are available in more than 100
countries, across core therapeutic areas including Hematology, Immunology,
Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal /
Internal Medicine / Endocrine and Hereditary Angioedema; and a growing
franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and
deliver breakthrough therapies for the hundreds of millions of people in the
world affected by rare diseases and other high-need conditions, and who lack
effective therapies to live their lives to the fullest.



www.shire.com

Shire plc published this content on 06 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 06 January 2017 11:07:05 UTC.

Original documenthttp://otp.investis.com/clients/uk/shire/rns/regulatory-story.aspx?cid=1027&newsid=833663

Public permalinkhttp://www.publicnow.com/view/1AE66606E1B5F9630B2907F61907FBEE861868EF